AI Article Synopsis
- The paper presents analytical formulas for the phase shifts of electron waves influenced by a spherical, magnetized particle with a specific inner potential.
- The study includes simulations using Foucault and Fresnel Lorentz techniques across various sizes and magnetic saturations of the particles.
- The findings, particularly in experimental electron holography of nanocrystalline cobalt particles, confirm the predicted phase shifts, highlighting the effectiveness of this method.
Article Abstract
This paper derives analytical expressions for the magnetic and electrostatic phase shifts of a plane electron wave upon traversing a spherical, uniformly magnetized particle with a non-zero mean inner potential. The Aharonov-Bohm phase shift is represented in terms of dimensionless parameters. Standard Foucault and Fresnel Lorentz image simulations are presented for a range of particle sizes and saturation inductions. We discuss the detection limits of the Lorentz techniques and compare them with the sensitivity of the electron holography method. We conclude the paper with experimental holography results for nanocrystalline cobalt particles; the observed phase changes are in good agreement with the analytical predictions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2818.1999.00444.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Scant Evidence for Long-Range Atmospheric Transport of Particle-Bound Benzotriazole Ultraviolet Stabilizers.
Environ Sci Technol
January 2025
Department of Physical and Environmental Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, Ontario, Canada M1C 1A4.
Despite benzotriazole UV stabilizers (BT-UVs) being widely used since the 1960s, few empirical data on their atmospheric presence exist. UV-328 was added to the Stockholm Convention on Persistent Organic Pollutants, based in part on model calculations indicating atmospheric long-range transport potential. We investigated the atmospheric occurrence of BT-UVs at multiple sites that differ greatly in their proximity to potential sources.
View Article and Find Full Text PDFSix-month Rituximab-Lenalidomide regimen in advanced untreated Follicular Lymphoma: SAKK 35/10 Trial 10-year Update.
Blood Adv
January 2025
Ente Ospedaliero Cantonale, Switzerland.
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).
View Article and Find Full Text PDFMRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.
Blood
January 2025
Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.
View Article and Find Full Text PDFCo-Designing a Digital Brief Intervention to Reduce the Risk of Prescription Opioid-Related Harm Among People With Chronic Noncancer Pain: Qualitative Analysis of Patient Lived Experiences.
JMIR Form Res
January 2025
Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Background: Opioid medications are important for pain management, but many patients progress to unsafe medication use. With few personalized and accessible behavioral treatment options to reduce potential opioid-related harm, new and innovative patient-centered approaches are urgently needed to fill this gap.
Objective: This study involved the first phase of co-designing a digital brief intervention to reduce the risk of opioid-related harm by investigating the lived experience of chronic noncancer pain (CNCP) in treatment-seeking patients, with a particular focus on opioid therapy experiences.
Background: Assisted partner services (APSs; sometimes called index testing) are now being brought to scale as a high-yield HIV testing strategy in many nations. However, the success of APSs is often hampered by low levels of partner elicitation. The Computer-Assisted Self-Interview (CASI)-Plus study sought to develop and test a mobile health (mHealth) tool to increase the elicitation of sexual and needle-sharing partners among persons with newly diagnosed HIV.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!